These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 38529674)
1. Improvements in Patient-Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial. Strand V; Gossec L; Coates LC; Ogdie A; Choi J; Becker B; Zhuo J; Lehman T; Nowak M; Elegbe A; Mease PJ; Deodhar A Arthritis Care Res (Hoboken); 2024 Aug; 76(8):1139-1148. PubMed ID: 38529674 [TBL] [Abstract][Full Text] [Related]
2. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. Kavanaugh A; McInnes IB; Krueger GG; Gladman D; Beutler A; Gathany T; Mack M; Tandon N; Han C; Mease P Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1666-73. PubMed ID: 23666608 [TBL] [Abstract][Full Text] [Related]
3. Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial. Strand V; Alemao E; Lehman T; Johnsen A; Banerjee S; Ahmad HA; Mease PJ Arthritis Res Ther; 2018 Dec; 20(1):269. PubMed ID: 30522501 [TBL] [Abstract][Full Text] [Related]
4. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Chen L; Kudlacz E; Wu J; Cappelleri JC; Hendrikx T; Hsu MA RMD Open; 2019; 5(1):e000808. PubMed ID: 30713722 [TBL] [Abstract][Full Text] [Related]
5. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE. Strand V; Tundia N; Bergman M; Ostor A; Durez P; Song IH; Enejosa J; Schlacher C; Song Y; Fleischmann R Rheumatology (Oxford); 2021 Dec; 60(12):5583-5594. PubMed ID: 33590829 [TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318 [TBL] [Abstract][Full Text] [Related]
7. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. Strand V; Schiff M; Tundia N; Friedman A; Meerwein S; Pangan A; Ganguli A; Fuldeore M; Song Y; Pope J Arthritis Res Ther; 2019 Dec; 21(1):263. PubMed ID: 31791386 [TBL] [Abstract][Full Text] [Related]
8. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Graham D; Wang C; Cappelleri JC; Hendrikx T; Hsu MA RMD Open; 2019; 5(1):e000806. PubMed ID: 30713721 [TBL] [Abstract][Full Text] [Related]
9. Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1. Strand V; Mease PJ; Soriano ER; Kishimoto M; Salvarani C; Saffore CD; Zueger P; McDearmon-Blondell E; Kato K; Gladman DD Rheumatol Ther; 2021 Dec; 8(4):1789-1808. PubMed ID: 34636026 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Mease PJ; Deodhar AA; van der Heijde D; Behrens F; Kivitz AJ; Neal J; Kim J; Singhal S; Nowak M; Banerjee S Ann Rheum Dis; 2022 Jun; 81(6):815-822. PubMed ID: 35241426 [TBL] [Abstract][Full Text] [Related]
11. The effect of risankizumab on achieving minimal clinically important differences in patient-reported outcomes in patients with psoriatic arthritis: results from KEEPsAKE 1 and 2. Kristensen LE; Soliman AM; Papp K; Barcomb L; Eldred A; Östör A J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2120-2129. PubMed ID: 35920763 [TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial. Bergman M; Tundia N; Martin N; Suboticki JL; Patel J; Goldschmidt D; Song Y; Wright GC Arthritis Res Ther; 2022 Jun; 24(1):155. PubMed ID: 35751108 [TBL] [Abstract][Full Text] [Related]
13. Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study. Strand V; Schett G; Hu C; Stevens RM J Rheumatol; 2013 Jul; 40(7):1158-65. PubMed ID: 23588944 [TBL] [Abstract][Full Text] [Related]
14. Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2. Strand V; Van den Bosch F; Ranza R; Leung YY; Drescher E; Zueger P; Saffore CD; Lertratanakul A; Lippe R; Nash P Rheumatol Ther; 2021 Dec; 8(4):1827-1844. PubMed ID: 34661885 [TBL] [Abstract][Full Text] [Related]
15. Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis. Rahman P; Puig L; Gottlieb AB; Kavanaugh A; McInnes IB; Ritchlin C; Li S; Wang Y; Song M; Mendelsohn A; Han C; Arthritis Care Res (Hoboken); 2016 Dec; 68(12):1812-1822. PubMed ID: 27483458 [TBL] [Abstract][Full Text] [Related]
16. Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Rahman P; McInnes IB; Deodhar A; Schett G; Mease PJ; Shawi M; Cua DJ; Sherlock JP; Kollmeier AP; Xu XL; Sheng S; Ritchlin CT; McGonagle D Clin Rheumatol; 2024 May; 43(5):1591-1604. PubMed ID: 38472528 [TBL] [Abstract][Full Text] [Related]
17. The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial. Strand V; Kaeley GS; Bergman MJ; Gladman DD; Coates LC; Sherif B; Hur P; Parikh B; Gilloteau I; Mease PJ Lancet Rheumatol; 2022 Mar; 4(3):e208-e219. PubMed ID: 38288937 [TBL] [Abstract][Full Text] [Related]
18. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. Strand V; Pope J; Tundia N; Friedman A; Camp HS; Pangan A; Ganguli A; Fuldeore M; Goldschmidt D; Schiff M Arthritis Res Ther; 2019 Dec; 21(1):272. PubMed ID: 31815649 [TBL] [Abstract][Full Text] [Related]
19. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Gladman DD; Mease PJ; Cifaldi MA; Perdok RJ; Sasso E; Medich J Ann Rheum Dis; 2007 Feb; 66(2):163-8. PubMed ID: 17046964 [TBL] [Abstract][Full Text] [Related]
20. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial. Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]